Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial-Reference-Cited by-同舟云学术

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

Published:2019-12-05 Issue:6 Volume:34 Page:1694-1700
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Attarbaschi Andishe, ,Mann Georg,Zimmermann Martin,Bader Peter,Barisone Elena,Basso Giuseppe,Biondi Andrea,Cario Gunnar,Cazzaniga Gianni^ORCID,Colombini Antonella,Flotho Christian,Kuhlen Michaela^ORCID,Lang Peter,Lauten Melchior,Linderkamp Christin,Locatelli Franco,Lo Nigro Luca,Möricke Anja,Niggli Felix,Panzer-Grümayer Renate,Parasole Rosanna,Peters Christina^ORCID,Caterina Putti Maria,Rizzari Carmelo,Suttorp Meinolf,Valsecchi Maria Grazia,Conter Valentino,Schrappe Martin

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0670-y.pdf

Reference22 articles.

1. Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 2002;100:420–6.

2. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–14.

3. Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123:1470–8.

4. Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013;27:1497–503.

5. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N. Engl J Med. 1998;338:1663–71.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead;Cureus;2024-08-22

2. The use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease;Pediatric Hematology/Oncology and Immunopathology;2024-04-16

3. IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia;Biomedicines;2024-01-01

4. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study;Journal of Clinical Oncology;2023-12-14

5. Immunotherapies for Children and Adolescents with Acute Lymphoblastic Leukemia and Highly Malignant Lymphoma;Pädiatrie & Pädologie;2023-11-28